Pular para o conteúdo principal
Ranking Invest

ICPT - Intercept Pharmaceuticals, Inc.

Segmento: HealthcareIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Análise Ranking Invest

Valuation estimado
-$ 257.61 Mi
Último Balanço Atualizado: 3T2023

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 71.84 Mi

Dívida Líquida

$ 121.12 Mi

L4T

-$ 58.61 Mi

MM4T

-20.02%

Indicadores Básicos

ROE

-81.58%

Índices de Previsibilidade

Receita Líquida

D0.08

Lucro

F3.41

Margem

E1.13

Índices de Tendência

Receita Líquida

D1.64

Lucro

A10.79

Margem

A10.53

Índices de Endividamento

DIV/PAT

1.69

DIV/L4T

-2.07

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.